Human EpCAM x E. coli β-Gal Bispecific Antibody - Negative Control

Monoclonal scFv antibody against human EpCAM and β-galactosidase - Negative control

Anti-hEpCAM-βGal is a bispecific antibody that recognizes two sites: human epithelial cell adhesion molecule (hEpCAM) and E. coli β-galactosidase (β-Gal). It is used as a negative control for the Anti-hEpCAM-CD3 bispecific antibody that, like solitomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on EpCAM-positive tumor cells [1].

Human EpCAM (also known as CD326, Trop1) is a transmembrane, 40 kDa glycoprotein highly abundant in almost all human carcinomas, including colon, prostate, ovarian, or breast cancer [2]. In healthy tissue, EpCAM expression is generally low [1,2]. In cancer, EpCAM overexpression is responsible for tumor proliferation, invasion, and migration. Since it is often correlated with a poor prognosis, EpCAM represents an attractive therapeutic target [1].

Key features

• Reacts with human EpCAM
• Unable to interact with human CD3
• cFv of clinical relevant bispecific mAb solitomab
• Hexahistidine (His6) tag
• Provided azide-free
• Each lot is functionally tested

References:

1. Kebenko M, et al., 2018. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 7(8):e1450710 .
2. Brischwein K, et al., 2006. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 43(8):1129-43.